Sirt1 Regulates p53 Stability and Expression of Its Target S100B during Long-Term Potentiation in Rat Hippocampus

Bulletin of Experimental Biology and Medicine

Volumn 160, Issue 4, 2016, Pages 432-434

  Lisachev, P D ^a   Pustylnyak, V O ^b,c   Shtark, M B ^b  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b INSTITUTE OF MOLECULAR BIOLOGY AND BIOPHYSICS   (Russian Federation)

^c NOVOSIBIRSK STATE UNIVERSITY   (Russian Federation)

Author keywords

EX 527; long term potentiation; p53; pifi thrin ; Sirt1

Indexed keywords

PIFITHRIN BETA; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN S100B; SELISISTAT; SIRTUIN 1; UNCLASSIFIED DRUG; 6-CHLORO-2,3,4,9-TETRAHYDRO-1H-CARBAZOLE-1-CARBOXAMIDE; CARBAZOLE DERIVATIVE; FUSED HETEROCYCLIC RINGS; MESSENGER RNA; PIFITHRIN-BETA; S100B PROTEIN, RAT; SIRT1 PROTEIN, RAT; TOLUENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; HIPPOCAMPAL SLICE; HIPPOCAMPUS; LONG TERM POTENTIATION; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN STABILITY; RAT; REGULATORY MECHANISM; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; GENETICS; MALE; METABOLISM; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CARBAZOLES; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HIPPOCAMPUS; LONG-TERM POTENTIATION; MALE; RATS; RATS, WISTAR; RNA, MESSENGER; S100 CALCIUM BINDING PROTEIN BETA SUBUNIT; SIRTUIN 1; TOLUENE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84959105238     PISSN: 00074888     EISSN: 15738221     Source Type: Journal    
DOI: 10.1007/s10517-016-3189-5     Document Type: Article

References (15)

1. P. D. Lisachev, V. O. Pustylnyak, and M. B. Shtark, Bull. Exp. Biol. Med., 158, No. 1, 86-88 (2014).
2. P. D. Lisachev, V. O. Pustylnyak, and M. B. Shtark, Bull. Exp. Biol. Med., 158, No. 3, 333-335 (2015).
3. P. D. Lisachev, V. O. Pustylnyak, and M. B. Shtark, Ross. Fiziol. Zh., 100, No. 8, 953-963 (2014).
4. V. G. Skrebitskii and A. N. Chepkova, Uspekhi Fiziol. Nauk, 30, No. 4, 3-13 (1999).
5. R. K. Gary and D. A. Jensen, Mol. Pharm., 2, No. 6, 462-474 (2005).
6. S. Gonfloni, V. Iannizzotto, E. Maiani, et al., Biochem. Pharmacol., 92, No. 1, 149-156 (2014).
7. P. G. Komarov, E. A. Komarova, R. V. Kondratov, et al., Science, 285, 1733-1737 (1999).
8. K. Kuribayashi, and W. S. El-Deiry, Adv. Exp. Med. Biol., 615, 201-221 (2008).
9. S. Lain, J. J. Hollick, J. Campbell, et al., Cancer Cell., 13, No. 5, 454-463 (2008).
10. S. Nag, J. Qin, K. S. Srivenugopal, et al., J. Biomed. Res., 27, No. 4, 254-271 (2013).
11. Y. Ofi r-Rosenfeld, K. Boggs, D. Michael, et al., Mol. Cell., 32, No. 2, 180-189 (2008).
12. B. Peck, C. Y. Chen, K. K. Ho, et al., Mol. Cancer Ther., 9, No. 4, 844-855 (2010).
13. V. O. Pustylnyak, P. D. Lisachev, M. B. Shtark, and O. I. Epstein, Brain Res., 1394, 33-39 (2011).
14. V. O. Pustylnyak, P. D. Lisachev, and M. B. Shtark, Neural Plast., doi: 10.1155/2015/242158 (2015).
15. J. M. Solomon, R. Pasupuleti, L. Xu, et al., Mol. Cell. Biol., 26, No. 1, 28-38 (2006).